CoChat

MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically

Munkhbaatar, Enkhtsetseg, Dietzen, Michelle, Agrawal, Deepti, Anton, Martina, Jesinghaus, Moritz, Boxberg, Melanie, Pfarr, Nicole, Bidola, Pidassa, Uhrig, Sebastian, Höckendorf, Ulrike, Meinhardt, Anna-Lena, Wahida, Adam, Heid, Irina, Braren, Rickmer, Mishra, Ritu, Warth, Arne, Muley, Thomas, Poh, Patrina S. P., Wang, Xin, Fröhling, Stefan, Steiger, Katja, Slotta-Huspenina, Julia, van Griensven, Martijn, Pfeiffer, Franz, Lange, Sebastian, Rad, Roland, Spella, Magda, Stathopoulos, Georgios T., Ruland, Jürgen, Bassermann, Florian, Weichert, Wilko, Strasser, Andreas, Branca, Caterina, Heikenwalder, Mathias, Swanton, Charles, McGranahan, Nicholas, Jost, Philipp J. · 2020 · Nature Communications
Cited by 61

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Evasion of programmed cell death represents a critical form of oncogene addiction in cancer cells. Understanding the molecular mechanisms underpinning cancer cell survival despite the oncogenic stress could provide a molecular basis for potential therapeutic interventions. Here we explore the role of pro-survival genes in cancer cell integrity during clonal evolution in non-small cell lung cancer (NSCLC). We identify gains of MCL-1 at high frequency in multiple independent NSCLC cohorts, occurring both clonally and subclonally. Clonal loss of functional TP53 is significantly associated with subclonal gains of MCL-1 . In mice, tumour progression is delayed upon pharmacologic or genetic inhibition of MCL-1. These findings reveal that MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-18372-1

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 23

  1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clinicians 68, 394–424 (2018).
  2. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014). · DOI · Paper page
  3. Janic, A. et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat. Med. 24, 947–953 (2018). · DOI · Paper page
  4. Lieschke, E., Wang, Z., Kelly, G. L. & Strasser, A. Discussion of some “knowns” and some “unknowns” about the tumour suppressor p53. J. Mol. Cell Biol. 11, 212–223 (2018). · DOI
  5. Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med 374, 311–322 (2016). · DOI · Paper page
  6. Fernandez-Marrero, Y., Spinner, S., Kaufmann, T. & Jost, P. J. Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia 30, 2152–2159 (2016). · DOI
  7. Borner, M. M. et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br. J. Cancer 79, 952–958 (1999). · DOI
  8. Zhang, H. et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 30, 1963–1968 (2011). · DOI · Paper page
  9. Craig, R. W. et al. Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. Genomics 23, 457–463 (1994). · DOI
  10. Wesarg, E. et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J. Cancer 121, 2387–2394 (2007). · DOI
  11. Song, L., Coppola, D., Livingston, S., Cress, D. & Haura, E. B. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 4, 267–276 (2005). · DOI · Paper page
  12. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013). · DOI · Paper page
  13. Kelly, G. L. et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 28, 58–70 (2014). · DOI · Paper page
  14. Opferman, J. T. et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671–676 (2003). · DOI · Paper page
  15. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001). · DOI · Paper page
  16. Campbell, K. J. et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 9, 19 (2018). · DOI · Paper page
  17. Brinkmann, K. et al. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death Differ. 24, 2032 (2017). · DOI
  18. Weber, A. et al. Hepatocyte-specific deletion of the anti-apoptotic protein Mcl-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology (Baltimore. Md.) 51, 1226–1236 (2010). · DOI · Paper page
  19. Grabow, S., Delbridge, A. R., Aubrey, B. J., Vandenberg, C. J. & Strasser, A. Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing Pro-B cells to apoptosis. Cell Rep. 14, 2337–2347 (2016). · DOI · Paper page
  20. Grabow, S., Delbridge, A. R. D., Valente, L. J. & Strasser, A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 124, 3939 (2014). · DOI · Paper page
  21. Spinner, S. et al. Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia 30, 1520–1530 (2016). · DOI
  22. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011). · DOI · Paper page
  23. Anton, M. & Graham, F. L. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol. 69, 4600 (1995). · DOI · Paper page

Cited by

See all 61

Metadata

Authors
Munkhbaatar, E., Dietzen, M., Agrawal, D., Anton, M., Jesinghaus, M., Boxberg, M., Pfarr, N., Bidola, P., Uhrig, S., Höckendorf, U., Meinhardt, A.-L., Wahida, A., Heid, I., Braren, R., Mishra, R., Warth, A., Muley, T., Poh, P. S. P., Wang, X., Fröhling, S., Steiger, K., Slotta-Huspenina, J., van Griensven, M., Pfeiffer, F., Lange, S., Rad, R., Spella, M., Stathopoulos, G. T., Ruland, J., Bassermann, F., Weichert, W., Strasser, A., Branca, C., Heikenwalder, M., Swanton, C., McGranahan, N., & Jost, P. J.
Venue
Nature Communications
Published
2020-09-10
Volume
11
Issue
1
ISSN
2041-1723
Cited by
61
References
16
Language
en
Licence
Funders
Deutsche Krebshilfe (111783)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. https://app.cochat.ai/papers/10.1038/s41467-020-18372-1
The paper
Munkhbaatar, E., Dietzen, M., Agrawal, D., Anton, M., Jesinghaus, M., Boxberg, M., Pfarr, N., Bidola, P., Uhrig, S., Höckendorf, U., Meinhardt, A.-L., Wahida, A., Heid, I., Braren, R., Mishra, R., Warth, A., Muley, T., Poh, P. S. P., Wang, X., . . . Jost, P. J. (2020). MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications. https://doi.org/10.1038/s41467-020-18372-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.